Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients
Metrics: PDF 2065 views | HTML 1302 views | ?
Sohei Kobayashi1, Tyuji Hoshino2, Takaki Hiwasa3, Mamoru Satoh4, Bahityar Rahmutulla1,5, Sachio Tsuchida4, Yuji Komukai2, Tomoaki Tanaka1, Hisahiro Matsubara6, Hideaki Shimada7, Fumio Nomura4, Kazuyuki Matsushita1,8
1Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba City, Chiba 260-8670, Japan
2Department of Physical Chemistry, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan
3Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
4Divisions of Clinical Mass Spectrometry and Clinical Genetics, Chiba University Hospital, Chiba 260-8670, Japan
5Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba City, Chiba 260-8670, Japan
6Department of Academic Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
7Department of Gastroenterological Surgery, Toho University Omori Medical Center, Tokyo 143-8541, Japan
8Department of Laboratory Medicine & Division of Clinical Genetics and Proteomics Chiba University Hospital, Chiba 260-8670, Japan
Kazuyuki Matsushita, email: firstname.lastname@example.org
Keywords: auto-antibodies, cancer biomarker, colorectal cancer, far-upstream element-binding protein-interacting repressor (FIR) = poly(U)-binding-splicing factor (PUF60)
Received: June 29, 2016 Accepted: October 12, 2016 Published: October 15, 2016
Anti-PUF60, poly(U)-binding-splicing factor, autoantibodies are reported to be detected in the sera of dermatomyositis and Sjogren’s syndrome that occasionally associated with malignancies. PUF60 is identical with far-upstream element-binding protein-interacting repressor (FIR) that is a transcriptional repressor of c-myc gene. In colorectal cancers, a splicing variant of FIR that lacks exon2 (FIRΔexon2) is overexpressed as a dominant negative form of FIR. In this study, to reveal the presence and the significance of anti-FIRs (FIR/FIRΔexon2) antibodies in cancers were explored in the sera of colorectal and other cancer patients. Anti-FIRs antibodies were surely detected in the preoperative sera of 28 colorectal cancer patients (32.2% of positive rates), and the detection rate was significantly higher than that in healthy control sera (Mann–Whitney U test, p < 0.01). The level of anti-FIRs antibodies significantly decreased after the operation (p < 0.01). Anti-FIRs antibodies were detected in the sera of early-stage and/or recurrent colon cancer patients in which anti-p53 antibodies, CEA, and CA19-9 were not detected as well as in the sera of other cancer patients. Furthermore, the area under the curve of receiver operating characteristic for anti-FIRs antibodies was significantly larger (0.85) than that for anti-p53 antibodies or CA19-9. In conclusions, the combination of anti-FIRs antibodies with other clinically available tumor markers further improved the specificity and accuracy of cancer diagnosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.